ZUMA-1: What the Lymphoma Trial Found

What ZUMA-1 set out to test

ZUMA-1 was a phase 2 trial of axicabtagene ciloleucel, a CAR T-cell therapy. It enrolled 111 people at centers across several countries. All of them had a large B-cell lymphoma that kept growing despite the treatments guidelines recommend.

The trial had one arm. Nobody received a different treatment for comparison. Its main measure was the objective response rate: the share of people whose tumors shrank by a set amount or disappeared. Results ran in the New England Journal of Medicine in 2017. Kite Pharma and the Leukemia and Lymphoma Society funded the work.

Who "refractory" describes

Refractory means the cancer did not respond, or stopped responding. The people in ZUMA-1 had one of three diagnoses:

• Diffuse large B-cell lymphoma, the most common aggressive lymphoma in adults.
• Primary mediastinal B-cell lymphoma, which starts in the chest, behind the breastbone.
• Transformed follicular lymphoma, a slow-growing lymphoma that has shifted into a fast-growing one.

All three begin in B cells. B cells are white blood cells that normally produce antibodies. Standard first treatment mixes chemotherapy with rituximab, an antibody drug aimed at a B-cell surface protein called CD20. Most people do well on it. This trial was about the people who did not.

How the therapy is built

The therapy starts with the person's own blood. A machine separates out T cells, the immune system's killer cells, and the rest of the blood goes back.

Those T cells travel to a manufacturing site. A gene is added so the cells display a chimeric antigen receptor — a lab-made protein that sits on the cell surface and grips CD19, a marker carried by B cells. Modified cells are then multiplied into the hundreds of millions.

Before the infusion, the person receives low-dose cyclophosphamide and fludarabine. This step is called lymphodepletion, and it clears space so the new cells can expand. The target dose was 2 million CAR T cells per kilogram of body weight, given once. Our CAR T-cell therapy explainer covers what the weeks around that infusion look like.

Results

Manufacturing worked for 110 of the 111 people enrolled, or 99%. Of those, 101 people — 91% — actually received an infusion.

Among the people treated:

• 82% had an objective response.
• 54% had a complete response, meaning no cancer could be detected.
• At a median follow-up of 15.4 months, 42% still had a response, and 40% still had a complete response.
• 52% were alive at 18 months.

The durability figure carried the weight. A one-time infusion leaving four in ten people with no detectable disease more than a year later was not something earlier salvage treatment had offered.

Safety, and why this is not a community-clinic treatment

Severe or life-threatening side effects were the rule, not the exception. During treatment, grade 3 or higher events included low neutrophils in 78%, anemia in 43%, and low platelets in 38%. Neutrophils are the white cells that fight bacteria; platelets help blood clot.

Two problems are specific to CAR T-cell therapy:

• Cytokine release syndrome, severe in 13%. The activated cells flood the body with signaling proteins. High fever comes first, then blood pressure can drop and organs can struggle.
• Nervous system events, severe in 28%. These include confusion, tremor, and difficulty finding words. Most resolve, but they need watching hour by hour.

Three people died during treatment. Because both syndromes can escalate quickly, this therapy is delivered at certified centers with intensive care nearby.

What happened next

The FDA approved axicabtagene ciloleucel on October 18, 2017, for adults with large B-cell lymphoma that had progressed after at least two prior treatment regimens. NCI notes that the therapy was first developed in its own Surgery Branch and later licensed to Kite Pharma.

That made it the second CAR T-cell therapy cleared in the United States, a month after the first.

Symptoms that should not wait

Lymphoma often announces itself quietly. Book a visit if any of these last:

• A swollen lymph node in the neck, armpit, or groin that persists past three or four weeks or keeps enlarging, especially if it is painless.
• Night sweats heavy enough to change the sheets.
• A temperature above 100.4°F (38°C) that keeps returning without an infection behind it.
• Unintended weight loss over 10% of your body weight in six months.
• New chest pressure, cough, or a swollen face and arms, which can signal a mass in the chest.

If you already finished lymphoma treatment, report a returning lump or returning night sweats rather than waiting for the next scheduled scan.

What this trial cannot tell you

• One arm, no randomization. The 82% has no head-to-head comparison, so it cannot show how much better this is than the alternatives.
• The percentages count the 101 people infused. Ten enrolled people never reached infusion, and leaving them out makes the treatment look more reliable than the whole journey was.
• Median follow-up was 15.4 months. Cure rates over five or ten years were simply not knowable from this report.
• Serious nervous-system events hit 28% of people. That risk is part of the offer, not a footnote.
• Enrollment criteria filter for people fit enough to withstand the treatment, so results may not transfer to everyone with the same diagnosis. Trial phases sets out what a phase 2 study can and cannot settle.
• The trial studied one product in lymphoma. It says nothing about CAR T-cell therapy in solid tumors.

Sources

This article was written from the sources below, which were checked on the source-check date shown above.

• Neelapu SS and colleagues, "Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma," New England Journal of Medicine, 2017 (PMID 29226797): https://pubmed.ncbi.nlm.nih.gov/29226797/
• National Cancer Institute, Cancer Currents, "With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic," October 25, 2017: https://www.cancer.gov/news-events/cancer-currents-blog/2017/yescarta-fda-lymphoma
• U.S. Food and Drug Administration, YESCARTA product page: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel

How this page was made

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

See an error, old source, or unclear wording? Tell us.